The pharmaceutical company first set out to acquire Ardence in Oct 2023, through two sale and purchase agreements.
Hyphens Pharma has completed the second tranche of acquiring 17% of shares in Ardence Pharm for a consideration of $3.35 million, according to a bourse filing on May 9.
This is the second out of the three tranches that Hyphens set to undertake to acquire the remaining 58% stake it does not have in Ardence.
